TCBPY — TC Biopharm (Holdings) Income Statement
0.000.00%
Last trade - 00:00- $0.01m
- -$1.30m
Annual income statement for TC Biopharm (Holdings), fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 10-K | 10-K |
| Standards: | IFRS | IFRS | IFRS | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.43 | 1.98 | 1.98 | 3.84 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 10.1 | 8.32 | 9.34 | 15.9 | 14.2 |
| Operating Profit | -6.64 | -6.34 | -7.36 | -12.1 | -14.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.89 | -6.63 | -15 | -3.03 | -7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.07 | -5.46 | -13.6 | -1.31 | -5.91 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.07 | -5.46 | -13.6 | -1.31 | -5.91 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.07 | -5.46 | -13.6 | -1.31 | -5.91 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -34,602 | -33,154 | -77,424 | -30.6 | -153 |